资讯

Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year

Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the ...